COMy 2024 | Biomarkers of microbiota dysbiosis to predict treatment response in hematologic malignancies
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses knowledge gaps regarding the role of microbiota in hematologic malignancies. Evidence from patients with lymphoma treated with CAR-T therapy suggests a link between gut microbiota and treatment response, which may also apply to multiple myeloma. Dr Malard emphasizes the need for biomarkers of microbiota dysbiosis to predict treatment effectiveness and to restore microbiota before treatment. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
